Raftlin is recruited by neuropilin-1 to the activated VEGFR2 complex to control proangiogenic signaling by Bayliss, Asha et al.
                          Bayliss, A., Sundararaman, A., Granet, C., & Mellor, H. (2020). Raftlin is
recruited by neuropilin-1 to the activated VEGFR2 complex to control
proangiogenic signaling. Angiogenesis. https://doi.org/10.1007/s10456-020-
09715-z
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1007/s10456-020-09715-z
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Springer at
https://link.springer.com/article/10.1007/s10456-020-09715-z . Please refer to any applicable terms of use of the
publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Vol.:(0123456789) 
Angiogenesis 
https://doi.org/10.1007/s10456-020-09715-z
ORIGINAL ARTICLE
Raftlin is recruited by neuropilin‑1 to the activated VEGFR2 complex 
to control proangiogenic signaling
Asha L. Bayliss1 · Ananthalakshmy Sundararaman1 · Camille Granet1 · Harry Mellor1 
Received: 26 October 2019 / Accepted: 24 February 2020 
© The Author(s) 2020
Abstract
Background VEGFR2 (vascular endothelial growth factor receptor 2) is the major pro-angiogenic receptor in endothelial 
cells. Compared to other members of the receptor tyrosine kinase family, we know relatively few VEGFR2 signaling part-
ners. Our objective was to use mass spectrometry-based proteomics to identify novel binding partners of activated VEGFR2.
Methods We created an endothelial cell line stably expressing GFP-tagged VEGFR2 and isolated activated receptor com-
plexes. Analysis by mass spectrometry identified raftlin as a novel binding partner of VEGFR2.
Results We found that raftlin is recruited to the activated VEGFR2 complex via the co-receptor Nrp1 (neuropilin-1). We 
show that raftlin regulates the surface levels of Nrp1 in endothelial cells, controlling the availability of Nrp1 for VEGFR2 
interaction. Raftlin stabilizes active VEGFR2 at the cell surface by inhibiting endocytosis of the activated receptor. Raftlin 
also promotes recycling of internalized VEGFR2 to the cell surface. Raftlin alters the signaling outcomes of VEGFR2 
activation, inhibiting the activation of p38 and FAK (focal adhesion kinases) specifically. Both pathways are linked to cell 
migration in endothelial cells, and raftlin inhibits endothelial cell migration in response to VEGF.
Conclusion Nrp1 is an important co-receptor for VEGFR2; however, its functions are still only partially understood. We 
show that raftlin works with Nrp1 in endothelial cells to control intracellular trafficking of the activated VEGFR2. This 
modulates the response to VEGF and controls endothelial cell migration.
Keywords VEGF receptor · Angiogenesis · Neuropilin · Endothelial cell · Intracellular trafficking
Introduction
Endothelial cells (ECs) must respond to pro-angiogenic sig-
nals to exit their quiescent state and engage in the complex 
set of changes required for the formation of a new blood ves-
sel [1]. The major pro-angiogenic signal is vascular endothe-
lial growth factor (VEGF), which is secreted by ischemic tis-
sues to drive neovascularization. The major pro-angiogenic 
receptor on ECs is VEGF receptor 2 (VEGFR2). Activa-
tion of VEGFR2 drives a number of downstream signal-
ing pathways that promote the proliferation and survival of 
ECs as well as controlling the complex set of morphological 
changes and coordinated migrations that underpin the forma-
tion of a new vessel [2].
VEGFR2 is a member of the receptor tyrosine kinase 
family, which includes a number of related mitogenic and 
motogenic receptors. The best characterized of these is epi-
dermal growth factor receptor 1 (EGFR). EGFR signals to a 
similar set of signaling partners as VEGFR2 to control the 
proliferation and migration of epidermal cells [3]. Signifi-
cant effort has been made to map these downstream partners, 
with the use of quantitative proteomics to identify the com-
ponents of the active EGFR receptor complex. As a result, 
we have a detailed picture of EGFR interactome, which is 
now thought to comprise over 200 proteins [4–6]. Assem-
bling this information has been critical to understanding the 
complex signaling networks controlled by the receptor, and 
for identifying targets for drug development.
In contrast, we know a far smaller set of interactions for 
VEGFR2 and a far smaller number of validated signaling 
partners [2, 7]. Here, we use proteomic analysis of isolated 
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VEGFR2 complexes to identify novel signaling partners for 
this receptor. We show that the poorly characterized mem-
brane protein raftlin is recruited to the activated VEGFR2 
complex to control EC migration in response to VEGF. This 
study identifies a novel component of the VEGFR2 com-
plex and demonstrates the importance of proteomic analy-
sis in the development of our understanding of VEGFR2 
signaling.
Methods
Reagents
Human recombinant  VEGF165 was from Peprotech, Lon-
don, UK. Human recombinant  VEGF112 was from R&D 
Systems, Minneapolis, MN. A mouse monoclonal antibody 
to VEGFR2 (Clone No. 89,109) was from R&D Systems 
and was used for immunofluorescence microscopy and anti-
body uptake experiments. A rabbit monoclonal antibody to 
VEGFR2 (Clone No. 55B11) was from Cell Signaling Tech-
nologies (London, UK) and was used for western blotting. 
A goat anti-Nrp1 polyclonal antibody was from Santa Cruz 
Biotechnology, Dallas, TX. A rabbit polyclonal antibody 
to raftlin was from Proteintech, Manchester, UK. A mouse 
monoclonal antibody to EEA1 was from BD Bioscience, 
Oxford, UK. A rabbit monoclonal antibody to sodium/potas-
sium ATPase (Clone No. D4Y7E) was from Cell Signal-
ing Technologies. Antibodies to phosphorylated VEGFR2 
(Tyr1175 and Tyr1059), Erk1/2 (Thr202/Tyr204), Src 
(Tyr416), (FAK (Tyr397), FAK (Tyr925), PLCγ (Tyr793), 
and p38 (Thr180/Tyr182) were from Cell Signaling Tech-
nologies. Antibodies to phosphorylated FAK Tyr407 were 
from ThermoFisher Scientific, Loughborough, UK. Anti-
bodies to phosphorylated VEGFR2 (Tyr1214) were from 
R&D Systems. siRNA oligonucleotides targeting raftlin and 
Nrp1 were from Dharmacon, Lafayette, CO and had the fol-
lowing sequences: siRFTN-A, GAA AUU CGU UGG UGU 
UAU A; siRTN-B, GAG AAG AAA UGC ACA ACA G; siNrp1, 
CCA GAG AAU UAU GAUCA. A universal negative control 
siRNA oligonucleotide was from Sigma-Aldrich, Poole, UK. 
A plasmid encoding full-length human raftlin was created 
in the mammalian expression vector pcDNA3 (Takara Bio, 
Mountain View, CA).
Cell culture and transfection
Human umbilical vein ECs (HUVEC) from pooled donors 
were purchased from Lonza, Cambridge, UK and were 
cultured in complete EC growth media (EGM-2; Lonza). 
Conditionally immortalized kidney ECs (CiGEnC) were 
maintained in complete microvascular EC growth media 
(EGM-2 MV; Lonza) at 33 °C and switched to 37 °C for 
experimental work. Where indicated, cells were trans-
fected with siRNA oligonucleotides using GeneFECTOR 
lipid according to the manufacturer’s protocol (Venn Nova, 
Pompano Beach, FL) and used 48 h later. Transfections 
with expression vectors were performed using Lipo-
fectamine 2000 according to the manufacturer’s protocol 
(ThermoFisher Scientific).
Creation of a stable GFP‑VEGFR2 endothelial cell 
line
Human VEGFR2 cDNA was modified to replace the signal 
peptide with a strong IgG kappa signal peptide followed 
by enhanced GFP. The resultant mature protein has GFP 
fused at the natural VEGFR2 N-terminus. This construct 
was subcloned into the pLVXpuro vector (Takara Bio). 
Lentiviral particles were produced in a HEK293T pack-
aging line, using standard methods. Briefly, cells were 
transfected with pLVXpuro and the packaging vectors 
pMDG2 and psAX2, using polyethylenimine. After 48 h, 
the cell medium was added to CiGEnC cells overnight. 
The following day, the process was repeated with fresh 
virus. Cells were selected for stable expression in media 
supplemented with 2 µg/ml puromycin.
Isolation of VEGFR2 complexes and mass 
spectrometry
CiGEnCs stably expressing GFP-VEGFR2 or GFP were 
serum-starved for 1 h and then stimulated with 40 ng/ml 
VEGF for the indicated time points. The cells were then 
washed once with ice-cold PBS and harvested in lysis 
buffer (20 mM Tris pH7.5, 137 mM NaCl, 0.5% NP-40, 
1  mM EDTA, 2  mM sodium orthovanadate, 10  mM 
sodium fluoride) containing protease inhibitor cocktail 
(Sigma-Aldrich). Cell lysates were clarified by centrifu-
gation for 12 min at 12,000 × g and 4 °C. The lysates were 
then incubated with GFP-Trap agarose beads (ChromoTek, 
Martinsried, Germany) for 1 h with end-over-end rotation 
at 4 °C. The beads were washed three times with lysis 
buffer and the bound protein eluted by heating at 95 °C 
with SDS-PAGE sample buffer. Samples were run approxi-
mately 1 cm into the separating gel of an SDS-PAGE gel 
and then subjected to in-gel tryptic digestion. The result-
ing peptides were fractionated using an Ultimate 3000 
nanoHPLC system in line with an LTQ-Orbitrap Velos 
mass spectrometer (ThermoFisher Scientific). The raw 
data files were processed and quantified using Proteome 
Discoverer software v1.4 (ThermoFisher Scientific) and 
searched against the UniProt Human database using the 
SEQUEST algorithm.
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Immunofluorescence microscopy
Cells were prepared for confocal immunofluorescence 
microscopy by fixation in 4% paraformaldehyde. Confocal 
microscopy was performed using a Leica SP5 AOBS confo-
cal laser-scanning microscope with an attached Leica DM 
I6000 inverted microscope. Confocal sections were taken 
across the z-plane and processed to form a 2D projection 
representing the full depth of the cell culture.
Immunoprecipitation
HUVEC were serum-starved for 1 h followed by stimulation 
with 40 ng/ml VEGF for the indicated time points. Cells 
were then washed once with ice-cold PBS and harvested 
in lysis buffer (20 mM Tris pH7.5, 137 mM NaCl, 0.5% 
NP-40, 1 mM EDTA, 2 mM sodium orthovanadate, 10 mM 
sodium fluoride) containing protease inhibitor cocktail 
(Sigma-Aldrich). Cell lysates were clarified by centrifuga-
tion for 12 min at 12,000 × g and 4 °C. A sample was taken 
from the supernatant, which represented the input, and the 
remainder was added to VEGFR2, raftlin or IgG control 
antibody, as indicated. Following 30 min of end-over-end 
rotation at 4 °C, lysates were incubated with Protein G beads 
(Sigma-Aldrich; 10 µL packed beads per 500 µL of lysate) 
for a further 2 h with end-over-end rotation at 4 °C. The 
beads were then washed three times in lysis buffer at 4 °C 
and protein was extracted from the beads by heating at 95 °C 
with SDS-PAGE sample buffer. Equivalent volumes of all 
samples were resolved by SDS-PAGE and analyzed by west-
ern blotting.
Antibody uptake
HUVEC seeded on glass coverslips were serum-starved 
for 1 h, washed once with ice-cold basal EGM-2, and incu-
bated with VEGFR2 antibody for 25 min on ice. Cells were 
washed twice with ice-cold basal media followed by incu-
bation with VEGF at 37 °C. At the indicated time point, 
cells were washed once with ice-cold PBS and fixed with 4% 
paraformaldehyde for 15 min at room temperature. Stand-
ard immunofluorescence staining procedure was then fol-
lowed and images were taken on a confocal microscope, as 
described above. Vesicles were counted using the ‘Track-
mate’ function of Image J.
Biotinylation
HUVEC were serum starved and stimulated with VEGF 
where indicated. All following steps were performed at 4 °C. 
Cells were washed with complete PBS (Sigma-Aldrich) and 
incubated 0.2 mg/ml NHS-Biotin (ThermoFisher Scientific) 
in complete PBS for 30 min. The unreacted biotinylation 
reagent was quenched by incubation with 100 mM glycine. 
Cells were then solubilized in lysis buffer (20 mM Tris pH 
7.5, 137 mM NaCl, 1 mM EDTA, 1% NP40, 2 mM sodium 
orthovanadate, 10 mM sodium fluoride) containing pro-
tease inhibitor cocktail (Sigma-Aldrich). Cell lysates were 
centrifuged at 12,000 × g for 12 min at 4 °C and a sample 
was taken from the supernatant, which represented the total 
cellular protein. Streptavidin-agarose beads (Upstate Bio-
technology, Lake Placid, NY) were added to the remaining 
supernatant (20 µl packed beads per 500 µl lysate) and left 
to tumble at 4 °C for 1 h. Beads were collected by cen-
trifugation at 800 × g for 30 s at 4 °C and supernatant was 
removed—this sample represents the internal protein pool. 
The beads were then washed 3 times in lysis buffer at 4 °C 
and protein was extracted from the beads by heating at 95 °C 
with SDS-PAGE sample buffer—this represents the surface 
pool. Equivalent volumes of all three samples were resolved 
by SDS-PAGE and analyzed by western blotting.
Cell fractionation and ultracentrifugation
Two 10 cm dishes of HUVEC per condition were treated 
with control or raftlin siRNA. After 48 h, cells were serum-
starved and stimulated with 40 ng/ml VEGF for 30 min at 
37 °C. Cells were washed once with ice-cold PBS and once 
with ice-cold homogenizing buffer (HB; 250 mM sucrose, 
8 mM  CaCl2, 4 mM  MgCl2, 78 mM KCl, 10 mM EGTA, 
5 mM HEPES, pH 7.2) containing protease inhibitor cocktail 
(Sigma-Aldrich), followed by the addition of 1.1 ml of HB 
buffer per dish. The remainder of the steps were carried out 
on ice. Cells were scraped, collected into a 1.5 ml microcen-
trifuge tube, and passed ten times through an Isobiotec cell 
homogenizer containing a tungsten carbide ball bearing that 
gives a 10 µm clearance (Isobiotec, Heidelberg, Germany). 
Homogenates were centrifuged for 5 min at 1000 × g and 
4 °C. A sample of the supernatant was added to SDS-PAGE 
sample buffer to represent the input sample. 2 ml homogen-
ate was then placed on top of a 10–30% iodixanol gradient 
in an ultracentrifuge tube. After centrifugation at 24,700 × g 
for 18 h at 4 °C, 0.5 ml fractions were collected from the top 
of the tube and added to SDS-PAGE sample buffer. Equal 
volumes were resolved by SDS-PAGE and analyzed by west-
ern blotting.
Signaling assays
HUVEC were serum-starved, stimulated with VEGF for 
the indicated time points and then harvested in lysis buffer 
(20 mM Tris pH 7.5, 137 mM NaCl, 1% NP-40, 1 mM 
EDTA, 2 mM sodium orthovanadate, 10 mM sodium fluo-
ride) containing protease inhibitor cocktail (Sigma-Aldrich). 
Cell lysates were clarified by centrifugation for 12 min at 
12,000 × g and 4 °C. Lysates were then added to SDS-PAGE 
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sample buffer and heated at 95 °C. Equivalent volumes were 
resolved by SDS-PAGE and analyzed by western blotting.
Cell migration assays
For analysis of cell motility, HUVEC were transfected with 
control or raftlin siRNA. After 48 h, cells were seeded at 
low density to allow the observation of single cells. Cell 
motility was tracked over 14 h using an Incucyte ZOOM 
system (Essen Bioscience, Welwyn Garden City, UK). Cell 
velocity and directness of migration were calculated using 
Incucyte ZOOM software. For analysis of cell migration, 
HUVEC were transfected with control or raftlin siRNA. 
After 24 h, cells were seeded into a 96-well ImageLock 
plate (Essen Bioscience) and incubated for a further 24 h 
until confluent. Cells were serum-starved for 1 h and stimu-
lated with 40 ng/ml VEGF. A scratch was made in each well 
using the IncuCyte WoundMaker tool (Essen Bioscience) 
and the plate was installed in the IncuCyte ZOOM system. 
Images were taken at 10 × magnification every hour for 24 h. 
The percentage of wound closure was calculated using the 
Incucyte ZOOM software.
Statistical analysis
Statistical significance was determined using two-way 
ANOVA with a post-hoc Bonferroni multiple compari-
son test. * P < 0.05, ** P < 0.01, **** P < 0.001, **** 
P < 0.0001.
Results
Identification of novel binding partners of activated 
VEGFR2
In order to purify binding partners of VEGFR2, we cre-
ated a stable endothelial cell line expressing a GFP-tagged 
VEGFR2 receptor. We constructed a fusion protein whereby 
the signal peptide of VEGFR2 was replaced with the strong 
signal peptide from the IgG kappa light chain to promote 
successful surface expression. This was followed by a GFP 
cassette so that the mature receptor was tagged at its extra-
cellular N-terminus. This strategy left the intracellular C-ter-
minal domain free to interact with downstream signaling and 
trafficking partners. We used lentiviral transduction to allow 
stable expression of the construct in the CiGEnC endothelial 
cell line. CiGEnC are conditionally immortalized human 
kidney endothelial cells (ECs) and maintain expression of 
a wide range of endothelial markers [8]. The distribution of 
GFP-VEGFR2 in this cell line was essentially identical to 
that of the endogenous receptor in primary human umbilical 
vein ECs (HUVEC). Both cell types showed a characteristic 
vesicular pool that overlapped significantly with the early 
endosomal marker EEA1 ( [9]; Fig. 1a). The GFP-tagged 
receptor was activated normally by VEGF stimulation, with 
phosphorylation of the receptor itself, and of key pro-angi-
ogenic signaling partners (Fig. S1a).
Cells were stimulated with VEGF over a 30-min time 
course and VEGFR2 complexes were isolated by affinity 
purification using GFP-Trap agarose beads. The samples 
were analyzed by mass spectrometry using an LTQ-Orbitrap 
Velos mass spectrometer and compared to a CiGEnC line 
expressing GFP alone. The analysis identified VEGFR2 as 
the strongest hit, together with a number of known VEGFR2 
binding partners. The full proteomic datasets from three 
independent experiments are shown in Table 1 in the online-
only Data Supplement. The method was sensitive enough 
to detect binding of VEGF to the receptor, which remained 
associated with VEGFR2 across the time course (Fig. 1b). 
Fig. 1  Identification of novel VEGFR2 binding partners. a The 
localization of endogenous VEGFR2 (green) in HUVEC was com-
pared with that of GFP-VEGFR2 expressed in CiGEnC. The GFP-
tagged receptor showed a similar pattern of plasma membrane and 
vesicular localization. In both cases, VEGFR2 + vesicles co-localized 
extensively with the early endosomal marker EEA1. Bar = 10  µm. 
b CiGEnC expressing GFP-VEGFR2 were stimulated with 40  ng/
ml VEGF and VEGFR2 complexes were captured and analyzed by 
mass spectrometry. The graph shows the peak areas of five proteins 
detected in the VEGFR2 complex, a comparative measure of abun-
dance. None of these proteins were detected in immunoprecipitates 
from a control CiGEnC cell line transduced with GFP only. Bind-
ing of VEGF to the receptor could be detected, together with the 
recruitment of the well-characterized binding partners neuropi-
lin-1 and β-Trcp2. The novel VEGFR2 partner raftlin was identi-
fied in VEGFR2 complexes upon VEGF stimulation. Data are 
means ± SEM; n = 3
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As previously reported, VEGF stimulation promoted the 
binding of the important VEGFR2 co-receptor; neuropilin-1 
(Nrp1). We also saw recruitment of the ubiquitin E3 ligase 
b-Trcp2 (Fig. 1b), which plays a key role in mediating the 
degradation of the activated receptor [10, 11]. In addition to 
previously characterized VEGFR2 partners, we saw consist-
ent recruitment of raftlin to the activated receptor (Fig. 1b). 
Raftlin was matched to various accession numbers, depend-
ing on the run (Q14699, B4E2S3, G3XAJ6; Table 1 in the 
online-only Data Supplement). Raftlin is a poorly character-
ized membrane protein that has been shown to play a part 
in lymphocyte signaling [12, 13]. No previous work links 
raftlin to VEGFR2 signaling, or to a function in ECs.
Raftlin is recruited to activated VEGFR2 via Nrp1
We validated the interaction between VEGFR2 and raftlin 
through immunoprecipitation of endogenous raftlin from 
primary human ECs. Endogenous VEGFR2 co-immuno-
precipitated with raftlin upon VEGF stimulation (Fig. 2a). 
We confirmed the interaction in reverse by immunoprecip-
itating endogenous VEGFR2 and blotting for raftlin (Fig. 
S1b). Interestingly, endogenous Nrp1 also co-immunopre-
cipitated with raftlin and this was independent of VEGF 
stimulation (Fig. 2a). This suggested that raftlin may be 
recruited to active VEGFR2 indirectly via Nrp1. To test 
this, we compared complex formation in ECs stimulated 
with  VEGF112. This artificially truncated growth factor is 
incapable of binding Nrp1 but can still activate VEGFR2 
[14]. As previously published [14],  VEGF112 drove 
VEGFR2 activation to the same extent as the  VEGF165 
isoform but did not support formation of a VEGFR2-Nrp1 
complex (Fig. 2b). Similarly,  VEGF112 did not support 
the formation of a VEGFR2-raftlin complex (Fig. 2b). 
Incubation with the VEGFR2 kinase inhibitor SU5146 
completely blocked autophosphorylation of VEGFR2 in 
response to  VEGF165 but did not affect complex forma-
tion with either Nrp1 or raftlin (Fig. 2b). We conclude 
that raftlin exists as a pre-complex with Nrp1 in ECs and 
that this complex is recruited to activated VEGFR2 via the 
heterodimerization of VEGFR2 and Nrp1. This interac-
tion is independent of VEGFR2 phosphorylation. Raftlin 
shows 29% homology to the related protein raftlin-2 [13]. 
We did not detect raftlin-2 peptides by mass spectrometry 
Fig. 2  Raftlin is recruited to activated VEGFR2 via Nrp1. a HUVEC 
were stimulated with 40  ng/ml VEGF over a 60-min time course 
prior to immunoprecipitation of endogenous raftlin. Raftlin formed 
a pre-complex with Nrp1 and interacted with VEGFR2 upon VEGF 
stimulation. The control immunoprecipitation was with a non-specific 
IgG. Total cell lysates contained both the mature VEGFR2 and the 
lower molecular weight, immature receptor. Only the mature recep-
tor interacted with raftlin. b HUVEC were stimulated for 10 min with 
either 40 ng/ml VEGF165 or VEGF112. Where indicated, cells were 
pre-incubated with 5 μM SU5416 for 1 h. Endogenous raftlin or Nrp1 
was isolated from cell lysates by immunoprecipitation. Nrp1 and raft-
lin were only recruited to the activated VEGFR2 complex when cells 
were stimulated with VEGF165. Pre-treatment with SU5416 inhib-
ited VEGFR2 phosphorylation at Y1175 (P-VEGFR2) but did not 
affect complex formation with Nrp1-raftlin
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of VEGFR2 complexes (Table 1 in the online-only Data 
Supplement) and we were not able to detect raftlin-2 in 
immunoprecipitates of activated VEGFR2 (Fig. S1c). We 
conclude that the interaction with VEGFR2 is specific for 
raftlin.
Raftlin controls the surface localization of Nrp1
Raftlin has previously been reported to localize to choles-
terol-rich membrane domains at the surface of lympho-
cytes via fatty acylation [13]. Given the existence of a 
raftlin–Nrp1 complex (Fig. 2), we were interested in deter-
mining the sites of localization of raftlin and Nrp1 in ECs. 
The available raftlin antibodies did not have the required 
sensitivity to detect endogenous raftlin by immunofluores-
cence microscopy, and so we expressed raftlin in ECs by 
transient transfection to increase the signal. Endogenous 
Nrp1 was divided between the plasma membrane and a 
vesicular pool as previously reported ( [15]; Fig. 3a). Sur-
prisingly, raising the cellular expression of raftlin led to a 
loss of vesicular Nrp1, and a corresponding increase in the 
surface pool (Fig. 3a). Raftlin showed a diffuse distribu-
tion through the plasma membrane but was also detected 
in bright annular structures (Fig. 3a). These structures 
bore superficial resemblance to podosome rosettes and 
also to circular dorsal ruffles. Podosome rosettes are sites 
of turnover and remodeling of the extracellular matrix 
at the basal surface of ECs [16], whereas circular dorsal 
ruffles are sites of endocytosis at the apical surface [17]. 
A defining feature of both podosome rosettes and dorsal 
circular ruffles is their dependence on localized F-actin, 
which was absent from the raftlin rings (Fig. 3b). Instead, 
staining with the cholesterol-binding drug filipin showed 
that these structures were cholesterol-rich (Fig. 3c). These 
findings suggested that raftlin might act to stabilize the 
surface pool of Nrp1 through its anchoring to membrane 
microdomains. To investigate this, we used surface bioti-
nylation to quantify the surface and internal pools of Nrp1 
in the presence and absence of raftlin. We selected siRNA 
oligonucleotides that gave effective silencing of endog-
enous raftlin in ECs (Fig. S1d). Surface biotinylation was 
used to label total surface proteins, followed by capture 
on streptavidin beads. We then used western blotting to 
quantify the levels of surface (biotinylated) and intracel-
lular (non-biotinylated) Nrp1. Silencing of raftlin led 
to an approximately 30% decrease in total Nrp1, which 
was entirely due to a 50% reduction in the surface pool 
(Fig. 3d, S1e). On treatment with VEGF, the surface pool 
of Nrp1 remained constant in control cells; however, in 
cells depleted of raftlin, there was further loss of surface 
Nrp1 (Fig. 3d). We conclude that raftlin acts to stabilize 
Nrp1 at the EC surface, maintaining levels in resting cells 
and preserving surface Nrp1 upon VEGF stimulation.
Raftlin controls the internalization of VEGFR2
Anchoring of Nrp1 at the cell surface by raftlin would poten-
tially inhibit endocytosis of the VEGFR2-Nrp1 complex on 
activation. To examine this, we labeled surface VEGFR2 
in live ECs by incubation with a specific monoclonal anti-
body and then examined the internalization of the recep-
tor over a 30-min period of VEGF stimulation. In control 
ECs, VEGFR2 was internalized into a vesicular endosomal 
pool as expected; however, receptor uptake was completely 
blocked in cells overexpressing raftlin (Fig. 4a). We repeated 
the experiment in cells depleted of raftlin to determine the 
contribution of endogenous raftlin to VEGFR2 endocytosis. 
Silencing of raftlin caused a significant increase in the num-
ber of VEGFR2 + vesicles on VEGF stimulation (Fig. 4b, c). 
We used surface biotinylation to quantify the effect on the 
internalization of activated VEGFR2. Depletion of raftlin 
had no effect on the surface levels of VEGFR2 in resting 
cells; however, significantly more VEGFR2 was removed 
from the cell surface on VEGF stimulation (Fig. 4d), consist-
ent with the increased rate of internalization.
Nrp1 has been implicated in the recycling of VEGFR2 
back to the cell surface after endocytosis [15]. Given that 
loss of raftlin perturbed the distribution of Nrp1 between 
the surface and vesicular compartments (Fig. 3a), we were 
interested to see what happened to endocytosed VEGFR2 in 
ECs depleted of raftlin. To address this, we stimulated ECs 
for 30 min with VEGF and then fractionated cellular mem-
branes by density centrifugation. We used well-characterized 
markers of cell compartments to identify the fractions cor-
responding to the plasma membrane, early endosomes, and 
late endosomes on the gradient (Fig. 4e). In accordance with 
the surface biotinylation data (Fig. 3d), silencing of raftlin 
caused a marked loss of plasma membrane Nrp1, without 
affecting the internal cellular pool (Fig. 4f, S2). In contrast, 
silencing of raftlin caused accumulation of internalized 
VEGFR2 in the late endosomal compartment, consistent 
with an inhibition of receptor recycling (Fig. 4f, S2). We 
conclude that raftlin acts to inhibit VEGFR2 internalization 
through formation of a VEGFR2-Nrp1-raftlin complex at 
the cell surface. Raftlin also acts to promote recycling of 
internalized VEGFR2 by ensuring the availability of Nrp1 
at the cell surface to pair with the receptor in its journey 
though the cell.
Raftlin controls VEGFR2 signaling output
The intracellular trafficking of tyrosine kinase receptors 
plays a key role in shaping their signaling outputs [18]. Inter-
nalized activated VEGFR2 continues to signal from inside 
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the cell, and changes to the kinetics of VEGFR2 traffic alter 
the pattern and kinetics of signals generated by the recep-
tor [19, 20]. Association of VEGFR2 with its co-receptor 
Nrp1 has also been found to modulate VEGFR2 signaling. 
Previous studies have shown that Nrp1 generally enhances 
sensitivity of ECs to VEGF and acts specifically to change 
the signaling to specific downstream pathways [21]. Given 
the effects of raftlin on the trafficking of VEGFR2 and on 
the intracellular distribution of Nrp1, we were interested in 
determining if these changes affected the signaling output 
from the receptor.
In keeping with previous reports [22], we found that 
silencing of Nrp1 reduced VEGFR2 phosphorylation at 
Tyr1175 (Fig. S3). We saw a corresponding general decrease 
in activation of downstream signaling partners (Fig. S3). 
Previous work has shown that Nrp1 is specifically required 
Fig. 3  Raftlin controls the surface localization of Nrp1. a HUVEC 
were transiently transfected with raftlin (green) and stained for 
endogenous Nrp1 (red). Overexpression of raftlin caused loss of the 
intracellular vesicular pool of Nrp1 and an increase in the diffusely 
stained surface pool. Raftlin showed diffuse surface staining but was 
also concentrated in annular structures (arrowheads). b HUVEC 
were transfected with raftlin (green) and co-stained for F-actin (red). 
The annular raftlin structures do not contain F-actin filaments. c 
HUVEC were transfected with raftlin (green) and co-stained for 
cholesterol (red). The annular raftlin structures are cholesterol-rich. 
Bars = 10 µm. d HUVEC were transfected with raftlin siRNA or con-
trol. Cells were treated with or without 40 ng/ml VEGF for 30 min. 
Surface proteins were the biotinylated on ice and isolated using 
streptavidin beads. A representative western blot is shown in Figure 
ID in the online-only Data Supplement. Silencing of raftlin reduced 
surface Nrp1 and led to a further loss of surface Nrp1 on VEGF stim-
ulation. Data are means ± SEM (n = 3)
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for activation of p38 downstream of VEGFR2 [14]. Accord-
ingly, we found that silencing of Nrp1 abolished activation 
of this key signaling partner in response to VEGF stimula-
tion (Fig. S3). Silencing of raftlin had no effect on the phos-
phorylation of Tyr1175 of VEGFR2 in response to VEGF 
stimulation (Fig. 5). This is a major phosphorylation site on 
the activated receptor and recruits PLCγ [1]. Consistent with 
this, we saw no effect of raftlin depletion on the activation 
of PLCγ or Erk1/2, nor did we see an effect on the activa-
tion of Src (Fig. 5). Surprisingly, silencing of raftlin had the 
opposite effect to silencing of Nrp1 on p38 activation, with 
a significant increase in p38 phosphorylation in response to 
VEGF stimulation (Fig. 5). Intriguingly, silencing of raft-
lin increased the phosphorylation of VEGFR2 at Tyr1214, 
Fig. 4  Raftlin controls the internalization of VEGFR2. a HUVEC 
were transfected with untagged full-length raftlin (green) and pre-
labeled on ice with VEGFR2 antibody (red). Antibody uptake was 
measured after 30-min stimulation with 40  ng/ml VEGF. Overex-
pression of raftlin blocked VEGFR2 internalization into endosomes. 
Bar = 10  μm. b–c HUVEC were transfected with raftlin siRNA or 
control and the same uptake experiment performed. Silencing of 
raftlin significantly increased the internalization of VEGFR2 into 
endosomes. Data are means ± SEM (n = 3). d HUVEC were trans-
fected with raftlin siRNA or control. Cells were treated ± 40  ng/ml 
VEGF for 30 min. Surface proteins were the biotinylated on ice and 
isolated using streptavidin beads. Silencing of raftlin had no effect 
on surface VEGFR2 in unstimulated cells but led to increased inter-
nalization on VEGF-stimulation. Data are means ± SEM (n = 3). 
e HUVEC cellular membranes were purified by density centrifuga-
tion. Western blotting of gradient fractions revealed the positions of 
the plasma membrane (PM), early endosome (EE), and late endosome 
(LE) fractions. f HUVEC were treated with raftlin siRNA or control 
and stimulated with 40  ng/ml VEGF for 30  min. The intracellular 
distributions of Nrp1 and VEGFR2 were determined by western blot-
ting of gradient fractions. Silencing of raftlin caused a loss of surface 
Nrp1 and an increase of VEGFR2 in late endosomal fractions. Data 
are means ± SEM (n = 4)
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the site responsible for p38 activation [2], although this 
trend did not achieve statistical significance (Fig. 5). Previ-
ous studies have provided evidence that Nrp1 is required 
for the phosphorylation of focal adhesion kinase (FAK) 
downstream of VEGFR2 activation; specifically, at Tyr407 
[2]. Those studies used a Nrp1 mutant that was unable to 
bind VEGFR2 [23]. We found that silencing of Nrp1 did 
not affect FAK phosphorylation at Tyr407 (Fig. 3). Simi-
larly, silencing of raftlin did not affect phosphorylation of 
this site either (Fig. 5). We examined the phosphorylation 
of FAK at two other sites: Tyr397 and Tyr925. Phospho-
rylation of Tyr397 is a marker of FAK activation [24] and 
Tyr397 is a major target of phosphorylation downstream of 
VEGFR2 activation [25]. Tyr925 is a minor site of phos-
phorylation in FAK downstream of VEGFR2 activation 
[26]. Interestingly, silencing of either Nrp1 or raftlin led to 
a significant increase in FAK phosphorylation at both sites 
(Fig. 5, S3). We conclude that raftlin acts to change the bal-
ance of signals produced by VEGFR2, leaving activation of 
the Src and Erk1/2 pathways unchanged, but suppressing the 
activation of p38 and FAK.
Raftlin controls endothelial cell migration
The best-characterized role for Nrp1 in VEGFR2 signal-
ing is in the regulation of EC migration [21]. Several stud-
ies have demonstrated that Nrp1 enhances the effects of 
VEGFR2 activation on motility [14, 23, 27]. There appear 
to be multiple mechanisms by which Nrp1 can do this. Nrp1 
is required for the activation of p38 by VEGFR2 [14] and 
Fig. 5  Raftlin regulates VEGFR2 signaling. HUVEC were trans-
fected with raftlin siRNA or control and then stimulated with 40 ng/
ml VEGF over a time course of 30 min. The activation of key down-
stream VEGFR2 signaling partners was quantified by western blot-
ting and densitometry. Depletion of raftlin had no significant effect on 
VEGFR2 activation, but instead specifically increased the activation 
of p38 and FAK. Data are means ± SEM from multiple independent 
experiments, as indicated in the panels
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p38 activation is required for VEGF-induced chemotaxis 
[28]. There is also evidence to support a requirement Nrp1 
in the phosphorylation of p130Cas downstream of VEGFR2, 
which is also required for chemotaxis [22]. Finally, phospho-
rylation of FAK at Tyr407 has also been linked to the regula-
tion of EC migration by Nrp1 [2]. We did not see changes 
to p130Cas phosphorylation in ECs on silencing of either 
Nrp1 or raftlin (data not shown), and we did not see changes 
to FAK phosphorylation at Tyr407 (Fig. 5, S3). We did see 
increased activation of p38 on silencing of raftlin (Fig. 5) 
and increased activation of FAK (Fig. 5). Importantly, we 
saw increases in FAK phosphorylation at Tyr925, which is 
also linked to increased cell migration [29].
We examined FAK activation in ECs by immunofluo-
rescence microscopy. Silencing of raftlin led to a dramatic 
increase in staining for active FAK (Tyr397), which was 
localized to focal adhesions at the cell periphery (Fig. 6a). 
Activation of FAK leads to the turnover of these adhesive 
contacts, promoting cell migration [24]. We measured 
the motility of ECs by tracking the random movements 
of single cells. Silencing of raftlin led to an increase in 
the velocity of movement and a decrease in directness 
(Fig. 6b). Directness is defined as the ratio between the 
Euclidian distance traveled (the distance between the start 
and end point) and the total distance traveled. A decrease 
in directness shows that cells are moving in a less persis-
tent manner, with increased changes in direction. Small 
changes in cell velocity and persistence become magni-
fied over distance during chemotaxis. We analyzed the 
migration of ECs in response to VEGF-stimulation using 
the well-characterized scratch migration model. Silenc-
ing of raftlin significantly increased the migration of ECs 
in response to VEGF (Fig. 6c). We conclude that raftlin 
acts to modulate the VEGFR2 signaling response by sup-
pressing cell migration, while leaving activation of the 
proliferative Erk1/2 pathway untouched.
Fig. 6  Raftlin regulates EC migration a HUVEC were transfected 
with raftlin siRNA or control and then stimulated with 40  ng/ml 
VEGF for 5  min. Depletion of raftlin increased the intensity of 
staining of autophosphorylated FAK (Tyr397) at focal adhesions. 
Bar = 10 µm. b HUVEC were transfected with raftlin siRNA or con-
trol and then plated at low density to allow tracking of cell move-
ment over 14  h. The average velocity and directness of cells were 
quantified. Directness was calculated as the ratio of the Euclidian 
distance traveled to the total migrated distance, with a value of 1 
corresponding to a cell moving in a straight line. Silencing of raftlin 
increased cell velocity and decreased directness of movement. Data 
are means ± SEM (n = 5). c HUVEC were transfected with raftlin 
siRNA or control and subjected to a scratch migration assay stimu-
lated with 40 ng/ml VEGF. Silencing of raftlin significantly increased 
cell migration. Data are means ± SEM (n = 6). The panels show repre-
sentative images obtained 16 h post wounding
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Discussion
Here, we show that raftlin is a novel regulator of VEGFR2, 
controlling both its intracellular trafficking and signaling 
output. Raftlin was first identified as a major component 
of lipid rafts in B-cells, where it regulates signaling from 
the B-cell receptor [13]. In ECs, lipid rafts facilitate 
VEGFR2 dimerization [2]. VEGF causes the release of 
activated VEGFR2 from lipid rafts, freeing it for inter-
nalization through clathrin-mediated endocytosis [30]. The 
internalization of Nrp1 has been shown to comprise two 
routes in ECs—stimulation with VEGF leading to endocy-
tosis of Nrp1 via the clathrin-dependent pathway, whereas 
stimulation with semaphorin 3C leading to internaliza-
tion via lipid rafts [31]. We find that raised expression of 
raftlin stabilizes the surface pool of Nrp1 and inhibits the 
endocytosis of activated VEGFR2 (Fig. 4). Conversely, 
depletion of the normal cellular pool of raftlin results in a 
significant loss of surface Nrp1 and an increase in endo-
cytosis of activated VEGFR2 (Fig. 4). These findings sup-
port a model whereby raftlin stabilizes Nrp1 at the cell 
surface by anchoring it to lipid rafts. These raftlin–Nrp1 
complexes then capture activated VEGFR2 and block its 
release from rafts, inhibiting its subsequent endocytosis 
through clathrin-dependent mechanisms. By increasing the 
pool of surface Nrp1 available for interaction with acti-
vated VEGFR2, raftlin would also support the recycling of 
internalized receptor [15] and we consequently see accu-
mulation of VEGFR2 in the late endosomal compartment 
in ECs depleted of raftlin (Fig. 4d).
Regulation of the kinetics and routes of receptor traf-
ficking is an important part of shaping the signaling output 
[18]. We find that raftlin has no effect on activation of the 
Erk1/2 pathway (Fig. 5), which controls EC proliferation 
in response to VEGFR2 activation [7]. We find that raftlin 
acts to suppress activation of p38, however (Fig. 5), which 
is required for the chemotactic response of ECs to VEGF 
[28]. Both raftlin and Nrp1 suppress the activation of FAK 
(as judged by phosphorylation of Tyr397), and also sup-
press the phosphorylation of Tyr925 (Fig. 5, S3), which is 
linked to increased cell motility [29]. Suppression by raft-
lin of Tyr925 phosphorylation is far greater than by Nrp1, 
suggesting that the dominant effect is supplied by raftlin. 
During angiogenesis, stalk cells at the base of the angio-
genic sprout undergo proliferation in response to VEGF 
but do not show chemotactic motility. Conversely, tip cells 
do not proliferate but sense the chemotactic VEGF gradi-
ent [32, 33]. These coordinated and reciprocal responses 
are critical for the integrity and collective migration of 
the chord. Nrp1 is required for chemotactic sensing of 
VEGF by the tip cell [34], supporting its pro-migratory 
role in ECs. It will be important to examine the relative 
expression of raftlin in stalk and tip cells during angio-
genesis to determine if this contributes to this differential 
response to VEGFR2 activation in the two cell subtypes.
The identification of raftlin as a novel component of 
the activated VEGFR2 signaling complex highlights that 
there are still important parts of the molecular mechanisms 
of VEGFR2 signaling to be identified. It is likely that the 
VEGFR2 proteome presented here contains further novel 
components of this network and we are currently working 
to validate additional new partners. It is clear that normal 
cellular levels of raftlin make a direct and significant contri-
bution to the signaling output of VEGFR2 activation in ECs. 
One important remaining question is how raftlin itself may 
be regulated. Recent studies have shown that raftlin is highly 
upregulated in the serum of septic patients, with evidence 
that this derives from increased expression in ECs [35]. It 
will be important to determine the mechanisms controlling 
the expression of raftlin in ECs, and how responses to physi-
ological and pathological conditions alter raftlin expression 
to regulate the cellular response to VEGFR2 activation.
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